Asset 26.png

Ana Guerreiro Stücklin

University Children's Hospital Zürich
Zürich, Switzerland



Swiss National Science Foundation

About this


Oncogenic fusions involving receptor tyrosine kinases (RTK) drive a group of low- and high-grade gliomas (LGG and HGG) in young children. The most common RTK rearrangements involve the oncogenes ALK/ROS1/NTRK/MET and provide an excellent opportunity for therapeutic targeting. These alterations are similar to those observed in multiple unrelated adult and pediatric tumor types, but their roles in gliomagenesis are still largely unknown.

The clinical features and natural history of pediatric RTK-driven gliomas remains uncharacterized. They are more common in infants but also prevalent in older children and adolescents. Interestingly, similar oncofusions drive both benign and malignant gliomas and additional genetic/epigenetic factors are likely to play a role in tumor behavior and explain the clinical heterogeneity.

Ask The


Ask the scientists

What are the goals of this project?

In this project, we seek to characterize the genetic, epigenetic and transcriptional landscape of RTK-driven pediatric LGG and HGG. To define clinically-relevant tumor subgroups and assess their prognostic significance, we will evaluate the correlation between molecular and clinical characteristics.

In a first step, we will analyze WGS, WES and RNAseq raw and processed data of gliomas (all grades) already generated by the Children's Brain Tumor Network. Integration of clinical data – including age, histology, tumor location, dissemination, time to progression(s) and overall survival - will allow us to identify the molecular characteristics that dictate clinical presentation and determine benign vs malignant behavior.

In a second step, we intend to expand the cohort and profile additional samples available through CBTN (a detailed separate request will be made for specimen access). Lastly, based on the mechanistic insights gained, we will design and validate new drug combination strategies to accelerate clinical translation.

What is the impact of this project?

Taken together, these studies will provide mechanistic insights into RTK-fused gliomas and enable precision medicine approaches to treat these tumors.

Meet The



Principal Investigator

Ana Guerreiro Stücklin, MD, PhD

Dr. Ana Guerreiro Stücklin is a pediatric oncologist. After her medical studies at the University of Porto, Portugal, she graduated from the MD-PhD Program at the University of Zurich and completed her pediatric residency at the University Children’s Hospital in Zurich. She was a pediatric hematolog


University Children's Hospital Zürich

Zürich, Switzerland

Cynthia Hawkins, MD, PhD, FRCPC

Molecular pathogenesis and therapeutics for paediatric astrocytomas, in particular diffuse intrinsic pontine glioma (DIPG)Identification and clinical implementation of novel prognostic and therapeutic markers for paediatric brain tumours


Sick Kids

Toronto, Canada

Uri Tabori, MD

The Tabori lab is focused on combining biological and translational research in paediatric oncology. Specifically, we are interested in studying mechanisms underlying brain tumor immortality and recurrence in the context of predisposition to cancer. Currently our group is studying 3 major areas rela


Sick Kids

Toronto, Canada

Scientific Committee

Executive Board

Scientific co-Chair

Principal Investigator

Adam Resnick, PhD

Adam Resnick is the Director of Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia (CHOP) responsible for leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. He is a


Children’s Hospital of Philadelphia

Philadelphia, PA, USA

Florence Cavalli


Anne-Marie Lyne, PhD

Default person avatar

Andreas Postlmayr, PhD